Martin Maier
Fortuna: - $ al 31/05/2026
Fortuna: - $ al 31/05/2026
Martin Maier currently works at Oligonucleotide Therapeutics Society, Inc., as Director, ProQR Therapeutics NV, as Member-Supervisory Board from 2024, and Alnylam Pharmaceuticals, Inc., as Senior Vice President-Oncology.
Dr. Maier received his doctorate degree in 1997 from Eberhard Karls Universität Tübingen.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 18/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Director/Miembro de la Junta | 22/05/2024 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2006 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Director/Miembro de la Junta | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Eberhard Karls Universität Tübingen
Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Commercial Services |
ProQR Therapeutics NV
ProQR Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.